RxDoctor Payments Data

Sami Almaskeen, MD

Gastroenterology · Saint Louis, MONPI 1992969307

Payments from drug & device makers

$4,190in general payments, 2019–2025

Across 151 payments — averaging $27.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • AbbVie$675
  • Olympus Corporation Of The Americas$382
  • Organon$287
  • Pfizer$243
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$225
  • plus $1K from 19 others

What the payments were for

  • Travel & lodging$1,12227%
  • Food & beverage$3,06873%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,190 in reported general payments places this provider in the 60th percentile of 374 gastroenterology providers in Missouri.

See all gastroenterology providers in Missouri

Medicare billing

Part B allowed, 2024
$255,546
Medicare patients
877
Services billed
2,253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase45$94,489
XifaxanRifaximin16$66,521
LinzessLinaclotide69$47,002
VoqueznaVonoprazan Fumarate13$7,912
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates118$7,183
Mesalamine ErMesalamine12$5,208
SutabSod Sulf/Pot Chloride/Mag Sulf22$3,451
CholestyramineCholestyramine (With Sugar)23$2,656
Pantoprazole Sodium188$2,063
Lubiprostone14$1,290
Omeprazole118$805
Famotidine79$784
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg38$678
Sucralfate20$636
Lactulose18$533

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$675$141,491114 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$225$66,52116 claims
Phathom Pharmaceuticals, Inc.Voquezna$14$7,91213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 374 gastroenterology providers in Missouri.

Other gastroenterology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →